On Thursday, BMS revealed that a phase 3 trial of Opdualag as an adjuvant treatment for patients with completely resected stage III and stage IV melanoma did not achieve its primary endpoint.

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

Comparison of laparoscopic radiofrequency ablation with percutaneous radiofrequency ablation in the treatment of chronic hepatitis B-related hepatocellular carcinoma involving specific sites: A ...

Global health inequalities in the burden of gastrointestinal cancers from 1990 to 2021 ...